Centrum für Hämatologie und Onkologie Bethanien — Clinical Trial Site

9 Registered trials

3 Currently recruiting

Organisation

Centrum für Hämatologie und Onkologie Bethanien

Location

Frankfurt, Germany

Identifier

ORL-000003467

Address

Im Prüfling 17-19, 60389, Germany

Departments

-
Centrum für Hämatologie und Onkologie
Centrum für Hämatologie und Onkologie Bethanien
Hämatologie und Onkologie
n.a.

Clinical trials at this site (9)

Search interface

Accelerate Improvement in Multiple Myeloma for Newly Diagnosed Transplant-Eligible Patients (AugMMent) Pending

2025-523990-40-00 Newly diagnosed Multiple Myeloma in patients eligible f 5
A study to evaluate the efficacy and safety of belantamab mafodotin in combination with standard of care in participants aged 18 years and o… Recruiting

2025-523117-28-00 Relapsed or Refractory Multiple Myeloma 4 2026-06-12
Adjuvant Dynamic marker - Adjusted Personalized Therapy comparing adjuvant Elacestrant with standard endocrine treatment in genomically and/… Recruiting

2025-522484-15-00 ER+/HER2- early breast cancer 5 2026-04-27
A randomized phase III trial assessing iberdomide versus iberdomide plus isatuximab maintenance therapy post autologous hematopoietic stem-c… Recruiting

2023-507402-13-00 Multiple myeloma 5 2024-04-03
Combination of Abemaciclib and endocrine therapy in hormone receptor positive HER2 negative locally advanced or metastatic breast cancer wit… Ended

2024-511209-49-00 Patients with hormone receptor positive HER2 negative l 6 2022-04-26
A randomized, controlled, open-label, phase III-trial on Adjuvant Dynamic marker - Adjusted Personalized Therapy comparing abemaciclib combi… Ended

2023-509242-35-00 HR+/HER2- early breast cancer 5 2020-07-23
Phase III Study of Capivasertib + Fulvestrant vs Placebo + Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic HR+/HER2… Ended

2023-505042-25-00 Locally advanced (inoperable) or metastatic HR+/HER2 br 5 2020-05-05
A randomized phase III non-inferiority trial assessing lenalidomide, bortezomib and dexame-thasone induction therapy with either intravenous… Ended

2024-516300-41-00 Multiple Myeloma 5 2023-03-07
A Randomized, Double-Blind, Phase III Clinical Trial of Neoadjuvant Chemotherapy with Atezolizumab or Placebo in Patients with Triple-Negati… Ended

2023-508472-11-00 Patients with early breast cancer 5 2018-06-13